Analysis of clinical features, prognosis and potential target genes of refractory meningioma-- Research based on multiple databases

Abstract

Objective: Analyzing SEER database data on malignant meningiomas, we explored high-risk factors for refractory meningiomas (RMs). Additionally, we analyzed GEO database genes across WHO grades to identify key genes and malignant risk factors for RMs. Immunohistochemical analysis was performed on WHO grade meningiomas' pathological specimens to verify hub gene expression differences. Methods: We included clinical cases of malignant meningiomas diagnosed in the SEER database. GEO database provided a gene expression profile dataset of 252 samples. Significant expression differences yielded screened genes, constructing a PPI network and identifying common hub genes. Hub gene-WHO classification correlation was assessed. A single center collected 38 meningioma samples grouped by WHO grade. Immunohistochemistry confirmed hub gene expressions. Results: SEER study: Multivariate COX analysis revealed age (P < 0.001), sex (P=0.071), chemotherapy (P < 0.001), and tumor size (P=0.003) as statistically significant prognostic factors. Gene database analysis: Differential genes ErbB3 and EGFR were identified; Progesterone and estrogen receptors PR and ER were also included, with distinct expressions across WHO grades (P < 0.001), except for ER. Pathological data study: EGFR correlated positively with WHO grade (r=0.396, P=0.014). ErbB3 (r=-0.487, p=0.002), ER (r=-0.396, P= 0.002), and egfr (r=-0.396, P=0.014) correlated negatively. nPR (r=-0.519, P < 0.001) and PR (r=-0.218, p=0.189) correlated negatively. nEGFR (r=-0.061, p=0.717) were not significant. ER (r=-0.316, P=0.065) and nPR (r=-0.443, P=0.008) correlated negatively with recurrence. Conclusion: EGFR, ErbB3, ER, and nPR might be potential RM diagnostic and treatment targets. mPR distribution discrepancies may hold diagnostic and therapeutic importance under new classifications or definitions.

EGFR-1 Expression in Meningioma: Insights into Gender Distribution and Grade

“…A recent study has reported that the expression of EGFR was observed to be more prevalent in meningioma of grade II and III as compared to those of grade I. 23 The research additionally discovered that the expression of EGFR was correlated with an increased likelihood of tumor recurrence and mortality.…”

“…16 Ciardiello et al, conducted a recent study that revealed that the expression of EGFR was linked to heightened tumor growth and invasion in cell lines of meningioma. 22,23 Ciardiello and colleagues have reported that the use of EGFR inhibitors can effectively target the overexpression of EGFR, resulting in a reduction in tumor growth and invasion in cell lines. 22 We did not find any significant correlation between the intensity of EGFR-1 expression and the grade of meningioma in Grade II meningioma cases (p=0.248).…”

“…16 Many studies have revealed that the expression of EGFR-1 was linked to an increased recurrence rate and a reduced time to recurrence, indicating that EGFR-1 could serve as a prognostic indicator for meningioma. 11,12,23 According to a recent study conducted by Li et al, the expression of EGFR was linked to an unfavorable prognosis among patients diagnosed with meningioma. 23 The research revealed that individuals exhibiting elevated levels of EGFR expression exhibited a reduced overall survival duration in comparison to those with lower levels of EGFR expression.…”

“…11,12,23 According to a recent study conducted by Li et al, the expression of EGFR was linked to an unfavorable prognosis among patients diagnosed with meningioma. 23 The research revealed that individuals exhibiting elevated levels of EGFR expression exhibited a reduced overall survival duration in comparison to those with lower levels of EGFR expression. A recent study has reported that the expression of EGFR was observed to be more prevalent in meningioma of grade II and III as compared to those of grade I.…”